Dexmedetomidine HCL (BXCL501) as a Potential Treatment for Alcohol Use Disorder and Comorbid PTSD: A Phase 1b, placebo-controlled crossover laboratory study

Journal: The American Journal on Addictions
Credit: 1.0 AMA PRA Category 1 Credits^TM
Release Date: December 13, 2024

Activity Disclosures

This activity received no commercial support.

The authors declare no conflicts of interest.

This activity underwent peer review in line with standards of editorial integrity and publication ethics. Conflicts of interest have been identified and resolved in accordance with John Wiley and Sons, Inc.’s Policy on Activity Disclosure and Conflict of Interest.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of John Wiley & Sons, Inc. and the American Academy of Addiction Psychiatry (AAAP). John Wiley & Sons, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

John Wiley and Sons, Inc. designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board. This activity is designed to be completed within 1 hour. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to two years from initial publication. Additionally, up to 3 attempts and a score of 100% or better is needed to pass the post test.